Bajaj Healthcare Limited Earnings Summary — Q4 FY2026

• Q4 results were impacted by a significant exceptional item involving the reversal of ₹3,324.66 Lakhs in Technical Know-how income due to Middle East instability.
• Total Operations reported a net loss of ₹2,285.06 Lakhs, swinging from a profit of ₹1,117.78 Lakhs in the same quarter last year.
• The board recommended a final dividend of 30% (₹1.50 per share) for the financial year 2025-26.
• The company successfully completed a preferential allotment, raising and utilizing ₹17,300.18 Lakhs for debt repayment and capital expenditure.
• Ongoing discontinued operations at Tarapur and Gujarat units contributed a loss after tax of ₹343.78 Lakhs during the quarter.
• Inventory levels rose significantly to ₹21,600.96 Lakhs from ₹16,188.77 Lakhs YoY, reflecting capital intensive business scaling.
• Acquisition of Genrx Pharmaceuticals is pending NCLT approval and has not yet been consolidated into financial results.

Management is focusing on high-value products and transition toward formulations, though execution on some high-margin projects has seen delays. Capital from recent equity infusions has been primarily directed toward balance sheet strengthening (debt repayment).

Deteriorating

The transition from a profitable quarterly run-rate to a significant loss due to a large income reversal and continued losses in discontinued operations suggests short-term instability.

The outlook depends on the successful stabilization of the Middle East technical transfer and the operationalization of the recently acquired Genrx facilities. While revenue remains stable, profitability is currently hampered by one-off adjustments and discontinued unit drags.